Search Prime Grants

R01DA057120

Project Grant

Overview

Grant Description
Characterization, optimization, and development of dual mGlu2/3 positive allosteric modulators for opioid use disorder.
Awardee
Sanford Burnham Prebys Medical Discovery Institute
Funding Goals
TO SUPPORT BASIC AND CLINICAL NEUROSCIENCE, BIOMEDICAL, BEHAVIORAL AND SOCIAL SCIENCE, EPIDEMIOLOGIC, HEALTH SERVICES AND HEALTH DISPARITY RESEARCH. TO DEVELOP NEW KNOWLEDGE AND APPROACHES RELATED TO THE PREVENTION, DIAGNOSIS, TREATMENT, ETIOLOGY, AND CONSEQUENCES OF DRUG ABUSE AND ADDICTION, INCLUDING HIV/AIDS. TO SUPPORT RESEARCH TRAINING AND RESEARCH SCIENTIST DEVELOPMENT. TO SUPPORT DISSEMINATION OF RESEARCH FINDINGS. SMALL BUSINESS INNOVATION RESEARCH (SBIR) LEGISLATION IS INTENDED TO EXPAND AND IMPROVE THE SBIR PROGRAMS TO EMPHASIZE AND INCREASE PRIVATE SECTOR COMMERCIALIZATION OF TECHNOLOGY DEVELOPED THROUGH FEDERAL SBIR RESEARCH AND DEVELOPMENT, INCREASE SMALL BUSINESS PARTICIPATION IN FEDERAL RESEARCH AND DEVELOPMENT, AND FOSTER AND ENCOURAGE PARTICIPATION OF SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERNS AND WOMEN-OWNED SMALL BUSINESS CONCERNS IN THE SBIR PROGRAM. THE LEGISLATION INTENDS THAT THE SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) PROGRAM STIMULATE AND FOSTER SCIENTIFIC AND TECHNOLOGICAL INNOVATION THROUGH COOPERATIVE RESEARCH AND DEVELOPMENT CARRIED OUT BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, FOSTER TECHNOLOGY TRANSFER BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, TO INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT, AND FOSTER AND ENCOURAGE PARTICIPATION OF SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERNS AND WOMEN-OWNED SMALL BUSINESS CONCERNS IN TECHNOLOGICAL INNOVATION.
Grant Program (CFDA)
93.279 - Drug Abuse and Addiction Research Programs
Awarding / Funding Agency
National Institute on Drug Abuse (NIDA) [HHS - NIH]
Place of Performance
California United States
Geographic Scope
State-Wide
Related Opportunity
Strategic Alliances for Medications Development to Treat Substance Use Disorders (R01-Clinical Trial Optional) (PAR-19-318)
Analysis Notes
Amendment Since initial award the End Date has been extended from 06/30/25 to 06/30/26.
Sanford Burnham Prebys Medical Discovery Institute was awarded Dual mGlu2/3 PAMs for Opioid Use Disorder Project Grant R01DA057120 worth $6,445,203 from National Institute on Drug Abuse in July 2022 with work to be completed primarily in California United States. The grant has a duration of 4 years and was awarded through assistance program 93.279 Drug Abuse and Addiction Research Programs. The Project Grant was awarded through grant opportunity Strategic Alliances for Medications Development to Treat Substance Use Disorders (R01-Clinical Trial Optional).

Status
(Ongoing)

Last Modified 9/24/25

Period of Performance
7/15/22
Start Date
6/30/26
End Date
82.0% Complete

Funding Split
$6.4M
Federal Obligation
$0.0
Non-Federal Obligation
$6.4M
Total Obligated
100.0% Federal Funding
0.0% Non-Federal Funding

Activity Timeline

Interactive chart of timeline of amendments to R01DA057120

Transaction History

Modifications to R01DA057120

Additional Detail

Award ID FAIN
R01DA057120
SAI Number
R01DA057120-1653244483
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
Nonprofit With 501(c)(3) IRS Status (Other Than An Institution Of Higher Education)
Awarding Office
75N600 NIH National Insitute on Drug Abuse
Funding Office
75N600 NIH National Insitute on Drug Abuse
Awardee UEI
PHMKYKKJLQS1
Awardee CAGE
1KBK8
Performance District
CA-90
Senators
Dianne Feinstein
Alejandro Padilla

Budget Funding

Federal Account Budget Subfunction Object Class Total Percentage
National Institute on Drug Abuse, National Institutes of Health, Health and Human Services (075-0893) Health research and training Grants, subsidies, and contributions (41.0) $6,445,203 100%
Modified: 9/24/25